Chiranjib Chakraborty, Zhi-Hong Wen, Govindasamy Agoramoorthy and Chan-Shing Lin Pages 469 - 477 ( 9 )
Background: Over the decade, miRNAs are the most important molecules for the biopharmaceutical industry due to their relation with several human diseases. Presently, the phase-II clinical trial has been initiated for the first miRNA-based therapeutics (“Miravirsen”) to treat HCV infection. It has been expected that many more miRNA-based therapeutics will enter the clinical trials. Therefore, it is important to develop different kinds of novel delivery systems with better efficacy and more efficiency, but fewer side effects.
Methods: We have undertaken a structured search of bibliographic databases for peer-reviewed research literature to solve our review question. Literature survey was performed widely to write this review article.
Results: In this review, we have discussed the various types of miRNA delivery systems such as viral vectors, lipid-based systems, nanocarriers, and LNA-customized DNA delivery without any delivery-mediated agent. Current status, technical support, and the future challenges for miRNA-based delivery are also discussed.
Conclusion: Recent development and understanding of miRNA had shown the therapeutic potentiality of miRNA.
Biopharmaceutical industry, cancer therapy, miRNA delivery, therapeutic microRNA, tumorigenesis.
Department of Marine Biotechnology and Resources, College of Marine Sciences, and Division of Marine Biotechnology, Asia-Pacific Ocean Research Center, National Sun Yatsen University, Kaohisung, Taiwan., Department of Marine Biotechnology and Resources, College of Marine Sciences, and Division of Marine Biotechnology, Asia-Pacific Ocean Research Center, National Sun Yatsen University, Kaohisung, Taiwan.